These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12660009)

  • 1. Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
    Fujiwara K; Kiura K; Ueoka H; Tabata M; Hamasaki S; Tanimoto M
    Lung Cancer; 2003 Apr; 40(1):73-6. PubMed ID: 12660009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.
    Kurata T; Tamura K; Kaneda H; Nogami T; Uejima H; Asai Go Go; Nakagawa K; Fukuoka M
    Ann Oncol; 2004 Jan; 15(1):173-4. PubMed ID: 14679138
    [No Abstract]   [Full Text] [Related]  

  • 3. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
    Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
    Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
    Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
    Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.
    Parra HS; Cavina R; Latteri F; Zucali PA; Campagnoli E; Morenghi E; Grimaldi GC; Roncalli M; Santoro A
    Br J Cancer; 2004 Jul; 91(2):208-12. PubMed ID: 15187994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
    Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
    BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
    Santoro A; Cavina R; Latteri F; Zucali PA; Ginanni V; Campagnoli E; Ferrari B; Morenghi E; Pedicini V; Roncalli M; Alloisio M; Ravasi G; Soto Parra HJ
    Ann Oncol; 2004 Jan; 15(1):33-7. PubMed ID: 14679116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
    Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
    Cohen MH; Williams GA; Sridhara R; Chen G; McGuinn WD; Morse D; Abraham S; Rahman A; Liang C; Lostritto R; Baird A; Pazdur R
    Clin Cancer Res; 2004 Feb; 10(4):1212-8. PubMed ID: 14977817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
    Argiris A; Mittal N
    Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.
    Suzuki T; Nakagawa T; Endo H; Mitsudomi T; Masuda A; Yatabe Y; Sugiura T; Takahashi T; Hida T
    Lung Cancer; 2003 Oct; 42(1):35-41. PubMed ID: 14512185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program.
    Razis E; Skarlos D; Briasoulis E; Dimopoulos M; Fountzilas G; Lambropoulos S; Rigatos S; Kopterides P; Efstathiou H; Tzamakou E; Bakoyannis C; Pectasides D; Makatsoris T; Varthalitis G; Papadopoulos S; Kosmidis P
    Anticancer Drugs; 2005 Feb; 16(2):191-8. PubMed ID: 15655417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.
    Magné N; Fischel JL; Tiffon C; Formento P; Dubreuil A; Renée N; Formento JL; Francoual M; Ciccolini J; Etienne MC; Milano G
    Br J Cancer; 2003 Aug; 89(3):585-92. PubMed ID: 12888834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gefitinib (ZD1839) on metastatic brain tumour.
    Takahashi H; Ohrui T; Ebihara S; Yamada M; Sasaki H
    Lung Cancer; 2004 Mar; 43(3):371-2. PubMed ID: 15165100
    [No Abstract]   [Full Text] [Related]  

  • 16. ZD1839 (Iressa) in non-small cell lung cancer.
    Herbst RS; Kies MS
    Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
    Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
    J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.
    Pallis AG; Mavroudis D; Androulakis N; Souglakos J; Kouroussis C; Bozionelou V; Vlachonikolis IG; Georgoulias V
    Lung Cancer; 2003 Jun; 40(3):301-7. PubMed ID: 12781429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
    Pectasides D; Visvikis A; Kouloubinis A; Glotsos J; Bountouroglou N; Karvounis N; Ziras N; Athanassiou A
    Eur J Cancer; 2002 Jun; 38(9):1194-200. PubMed ID: 12044505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer.
    Adjei AA; Argiris A; Murren JR
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):32-40; discussion 41-2. PubMed ID: 10585007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.